SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria. In large-scale randomized controlled trials, SGLT2 inhibitors reduce the risk of hospitalizations for heart failure by ∼30% and often decrease the risk of cardiovascular death (1). This benefit is particularly striking in patients who have the most marked impairment of systolic function prior to treatment. In parallel, SGLT2 inhibitors also reduce the risk of end-stage renal events, including the occurrence of renal death and the need for dialysis or renal transplantation by ∼30% (2). This benefit is seen even when glomerular filtration rates are sufficiently low to abolish the glycosuric effect of these drugs. These cardiorenal benefits cannot be explained by an action of SGLT2 inhibitors to lower blood glucose, since similar effects are not seen with antidiabetes drugs that have greater antihyperglycemic actions. Additionally, they cannot be ascribed to a natriuretic action, since these drugs exert only a modest effect on plasma volume or on circulating natriuretic peptides (3). In 2016, two articles published in Diabetes Care proposed the “thrifty fuel hypothesis” to explain the cardiorenal benefits of SGLT2 inhibitors. Ferrannini et al. (4) and Mudaliar et al. (5) postulated that the action of SGLT2 inhibitors to promote ketogenesis might account for their favorable effects on the heart and kidney because enhanced ketone bodies formation might possibly provide an efficient fuel that could boost the energy state of organs under stress. However, type 2 diabetes represents a state of nutrient overabundance and not energy deprivation, as is evidenced by the enhancement of molecular pathways that promote both energy retention (e.g., through SGLT2 upregulation) and energy storage (6,7). In fact, the stressed heart already preferentially utilizes ketone bodies, …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, according to Packer M, SGLT2 inhibitors cause transcriptional changes in cells that occur during starvation, which is called “state of fasting mimicry” and include SIRT/AMPK activation and Akt/mTOR suppression (Figure 3).”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
In the citing paper
“Moreover, taking flozins causes changes similar to an ischemic state, including HIF-2α activation which stimulates erythropoiesis, and patients with higher erythrocyte count benefited most from SGLT2i therapy.”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
Citations
Cites
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart
Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., Tian, B., Wagner, T., Vatner, S. F., & Sadoshima, J. (2007) · Circulation Research · doi:10.1161/01.res.0000267723.65696.4a · Cited by 1,147
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“Such a relationship may explainwhy, in statisticalmediation analyses, erythrocytosis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).”
BackgroundThe Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Regulation of Hypoxia-Inducible Factor 2α Signaling by the Stress-Responsive Deacetylase Sirtuin 1
Dioum, E. M., Chen, R., Alexander, M. S., Zhang, Q., Hogg, R. T., Gerard, R. D., & Garcia, J. A. (2009) · Science · doi:10.1126/science.1169956 · Cited by 472
Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370 · cited 1×
“with SGLT2 protein on an individual cellular level, since it is seen in organs that do not express SGLT2 (30,32).”
BackgroundDevelopment of autophagy inducers in clinical medicine
Levine, B., Packer, M., & Codogno, P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73938 · Cited by 347
Self-citationTerami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Ren, H., Shao, Y., Wu, C., Ma, X., Lv, C., & Wang, Q. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110628 · Cited by 313 · cited 1×
“Perhaps more importantly, coordinated activation of SIRT1/AMPK signaling stimulates autophagy (17,18).”
BackgroundSGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
Wang, X. X., Levi, J., Luo, Y., Myakala, K., Herman-Edelstein, M., Qiu, L., Wang, D., Peng, Y., Grenz, A., Lucia, S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779520 · Cited by 306
Chang, C., Su, H., Zhang, D., Wang, Y., Shen, Q., Liu, B., Huang, R., Zhou, T., Peng, C., Wong, C. C. L., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.037 · Cited by 286
Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes
Kanamori, H., Takemura, G., Goto, K., Tsujimoto, A., Mikami, A., Ogino, A., Watanabe, T., Morishita, K., Okada, H., Kawasaki, M., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1051295 · Cited by 234 · cited 1×
“In striking contrast, autophagic flux is increased in type 1 diabetes, potentially because it is the hyperinsulinemia of type 2 diabetesdrather than the hyperglycemiadthat causes downregulation of autophagy under conditions of glucose intolerance (20).”
BackgroundPacker, M. (2017) · Circulation · doi:10.1161/circulationaha.117.030418 · Cited by 230
Self-citationSGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Osataphan, S., Macchi, C., Singhal, G., Chimene-Weiss, J., Sales, V., Kozuka, C., Dreyfuss, J. M., Pan, H., Tangcharoenpaisan, Y., Morningstar, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123130 · Cited by 228 · cited 1×
“and the shrinkage of adipose tissue depots, including the alleviation of organ steatosis (27).”
BackgroundSirtuins and renal diseases: relationship with aging and diabetic nephropathy
Kitada, M., Kume, S., Takeda-Watanabe, A., Kanasaki, K., & Koya, D. (2013) · Clinical Science · doi:10.1042/cs20120190 · Cited by 207
Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress
Luo, G., Jian, Z., Zhu, Y., Zhu, Y., Chen, B., Ma, R., Tang, F., & Xiao, Y. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4125 · Cited by 187 · cited 1×
“Perhaps more importantly, coordinated activation of SIRT1/AMPK signaling stimulates autophagy (17,18).”
BackgroundDapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Chang, Y.-K., Choi, H., Jeong, J. Y., Na, K.-R., Lee, K. W., Lim, B. J., & Choi, D. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158810 · Cited by 176
Mizuno, M., Kuno, A., Yano, T., Miki, T., Oshima, H., Sato, T., Nakata, K., Kimura, Y., Tanno, M., & Miura, T. (2018) · Physiological Reports · doi:10.14814/phy2.13741 · Cited by 169
Aragón-Herrera, A., Feijóo-Bandín, S., Otero Santiago, M., Barral, L., Campos-Toimil, M., Gil-Longo, J., Costa Pereira, T. M., García-Caballero, T., Rodríguez-Segade, S., Rodríguez, J., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113677 · Cited by 163 · cited 1×
“with SGLT2 protein on an individual cellular level, since it is seen in organs that do not express SGLT2 (30,32).”
BackgroundUmino, H., Hasegawa, K., Minakuchi, H., Muraoka, H., Kawaguchi, T., Kanda, T., Tokuyama, H., Wakino, S., & Itoh, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-25054-y · Cited by 162
The role of SIRT1 in diabetic cardiomyopathy
Karbasforooshan, H., & Karimi, G. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.056 · Cited by 157
Laemmle, A., Lechleiter, A., Roh, V., Schwarz, C., Portmann, S., Furer, C., Keogh, A., Tschan, M. P., Candinas, D., Vorburger, S. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033433 · Cited by 153
Joo, H.-Y., Yun, M., Jeong, J., Park, E., Shin, H.-J., Woo, S. R., Jung, J. K., Kim, Y. M., Park, J., Kim, J., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.119 · Cited by 150
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.08.004 · Cited by 144 · cited 1×
“Such a relationship may explainwhy, in statisticalmediation analyses, erythrocytosis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).”
BackgroundChemical Constituents of Three Allium Species from Romania
Vlase, L., Parvu, M., Parvu, E., & Toiu, A. (2012) · Molecules · doi:10.3390/molecules18010114 · Cited by 128
Chen, S. C., Brooks, R., Houskeeper, J., Bremner, S. K., Dunlop, J., Viollet, B., Logan, P. J., Salt, I. P., Ahmed, S. F., & Yarwood, S. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.11.011 · Cited by 127
Takahashi, A., Takabatake, Y., Kimura, T., Maejima, I., Namba, T., Yamamoto, T., Matsuda, J., Minami, S., Kaimori, J.-Y., Matsui, I., et al. (2017) · Diabetes · doi:10.2337/db16-0397 · Cited by 122 · cited 1×
“In parallel, suppression of SIRT1/AMPK signaling and autophagy has been evoked to explain the pathogenesis of the glomerular and tubular lesions in diabetic nephropathy, particularly thepodocyte injury that can lead to proteinuria and the derangements of proximal and distal tubular function that have been linked to ad…”
BackgroundProteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes
Zhang, D., Yang, H., Kong, X., Wang, K., Mao, X., Yan, X., Wang, Y., Liu, S., Zhang, X., Li, J., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00308.2010 · Cited by 81
Li, X., Li, J., Wang, L., Li, A., Qiu, Z., Qi, L., Kou, J., Liu, K., Liu, B., & Huang, F. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13493 · Cited by 75
Li, H., Satriano, J., Thomas, J. L., Miyamoto, S., Sharma, K., Pastor-Soler, N. M., Hallows, K. R., & Singh, P. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00463.2014 · Cited by 74
AMPK signalling: Implications for podocyte biology in diabetic nephropathy
Szrejder, M., & Piwkowska, A. (2019) · Biology of the Cell · doi:10.1111/boc.201800077 · Cited by 69 · cited 1×
“In parallel, suppression of SIRT1/AMPK signaling and autophagy has been evoked to explain the pathogenesis of the glomerular and tubular lesions in diabetic nephropathy, particularly thepodocyte injury that can lead to proteinuria and the derangements of proximal and distal tubular function that have been linked to ad…”
BackgroundInoue, M.-K., Matsunaga, Y., Nakatsu, Y., Yamamotoya, T., Ueda, K., Kushiyama, A., Sakoda, H., Fujishiro, M., Ono, H., Iwashita, M., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0454-6 · Cited by 61
Paula-Gomes, S., Gonçalves, D., Baviera, A., Zanon, N., Navegantes, L., & Kettelhut, I. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1347209 · Cited by 58
Hypoxia induces autophagy in cardiomyocytes via a hypoxia-inducible factor 1-dependent mechanism
GUI, L., LIU, B., & LV, G. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3190 · Cited by 58 · cited 1×
“However, since both HIF-1a and HIF-2a appear to induce autophagy (49,50) in a manner than is independent of AMPK (39), it is possible that enhanced HIF-1a/HIF-2a signaling by SGLT2 inhibitors may amplify the autophagic flux that is already augmented by AMPK/SIRT1, thereby contrib-”
BackgroundAvogaro, A., Fadini, G. P., & Del Prato, S. (2020) · Diabetes Care · doi:10.2337/dc19-1410 · Cited by 51 · cited 1×
“(13) propose precisely the opposite hypothesis.”
Guh, J., Chuang, T., Chen, H.-C., Hung, W.-C., Lai, Y., Shin, S.-J., & Chuang, L.-Y. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00330.x · Cited by 49
Dietary sodium induces a redistribution of the tubular metabolic workload
Udwan, K., Abed, A., Roth, I., Dizin, É., Maillard, M. P., Bettoni, C., Loffing, J., Wagner, C. A., Edwards, A., & Féraille, E. (2017) · The Journal of Physiology · doi:10.1113/jp274927 · Cited by 49
Meijles, D. N., Zoumpoulidou, G., Markou, T., Rostron, K. A., Patel, R. K., Lay, K., Handa, B. S., Wong, B., Sugden, P. H., & Clerk, A. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.02.006 · Cited by 40
Kidney hemodynamics after ketone body and amino acid infusion in normal and IDDM subjects
Nosadini, R., Trevisan, R., Fioretto, P., Semplicini, A., Samà, B., Velussi, M., Luigi Da Campo, G., Avogaro, A., Vizzaccaro, A., Donadon, V., et al. (1989) · Diabetes · doi:10.2337/diab.38.1.75 · Cited by 34
Huang, D. Y., Gao, H., Boini, K. M., Oßwald, H., Nürnberg, B., & Lang, F. J. W. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0803-7 · Cited by 30
EPAS1/HIF-2α is a driver of mammalian pexophagy
Schönenberger, M. J., Krek, W., & Kovacs, W. J. (2015) · Autophagy · doi:10.1080/15548627.2015.1045180 · Cited by 24
Na+/H+ Exchanger Regulates Amino Acid-Mediated Autophagy in Intestinal Epithelial Cells
Shi, H., Zhao, X., Ding, Z., Han, C., Jiang, Y., Qian, W., Lin, R., & Hou, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480184 · Cited by 13
Research works printed but not linked: 1
- Balaiya, 2012, Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α, Mol Vis, 18, 114
Cited by
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 632
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
“An emerging theory links this to autophagy stimulation, including in the kidney and heart (20, 70, 97) (Figures 1 and 3).”
Background
Metadata
- Authors
- Packer, M.
- Affiliations
- Baylor University Medical Center (US)
- Corresponding author
- Packer, Milton
- ORCID
- Packer, Milton
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-02-11
- Volume
- 43
- Issue
- 3
- Pages
- 508-511
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3008610985
- Semantic Scholar
- 18ef104bcf8e540a8930b852692198f550512f79
- Cited by
- 247
- References
- 52
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 29 · 2023: 37 · 2022: 33 · 2021: 71 · 2020: 22
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, cardiorenal benefits, cellular reprogramming, ketogenesis, ketone bodies, heart failure hospitalization, end-stage renal disease, type 2 diabetes, energy metabolism
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Fasting, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.